Product Name
GLIS3, siRNA
Full Product Name
GLIS3 siRNA (Human)
Product Synonym Names
ZNF515; Zinc finger protein GLIS3; GLI-similar 3; Zinc finger protein 515
Product Gene Name
GLIS3 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q8NEA6
Specificity
GLIS3 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human GLIS3 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of GLIS3 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
GLIS3 sirna
siRNA to inhibit GLIS3 expression using RNA interference
Applications Tested/Suitable for GLIS3 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for GLIS3. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001035878.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001042413.1
[Other Products]
UniProt Primary Accession #
Q8NEA6
[Other Products]
UniProt Secondary Accession #
Q1PHK5; B1AL19[Other Products]
UniProt Related Accession #
Q8NEA6[Other Products]
Molecular Weight
99,605 Da
NCBI Official Full Name
zinc finger protein GLIS3 isoform a
NCBI Official Synonym Full Names
GLIS family zinc finger 3
NCBI Official Symbol
GLIS3??[Similar Products]
NCBI Official Synonym Symbols
ZNF515
??[Similar Products]
NCBI Protein Information
zinc finger protein GLIS3
UniProt Protein Name
Zinc finger protein GLIS3
UniProt Synonym Protein Names
GLI-similar 3; Zinc finger protein 515
Protein Family
Zinc finger protein
UniProt Gene Name
GLIS3??[Similar Products]
UniProt Synonym Gene Names
ZNF515??[Similar Products]
UniProt Entry Name
GLIS3_HUMAN
NCBI Summary for GLIS3
This gene is a member of the GLI-similar zinc finger protein family and encodes a nuclear protein with five C2H2-type zinc finger domains. This protein functions as both a repressor and activator of transcription and is specifically involved in the development of pancreatic beta cells, the thyroid, eye, liver and kidney. Mutations in this gene have been associated with neonatal diabetes and congenital hypothyroidism (NDH). Alternatively spliced variants that encode different protein isoforms have been described but the full-length nature of only two have been determined. [provided by RefSeq, Jul 2008]
UniProt Comments for GLIS3
GLIS3: Acts as both a repressor and activator of transcription. Binds to the consensus sequence 5'-GACCACCCAC-3'. Defects in GLIS3 are a cause of diabetes mellitus neonatal with congenital hypothyroidism (NDH). NDH is a neonatal diabetes syndrome associated with congenital hypothyroidism, congenital glaucoma, hepatic fibrosis and polycystic kidneys. Belongs to the GLI C2H2-type zinc-finger protein family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: C2H2-type zinc finger protein; Transcription factor
Chromosomal Location of Human Ortholog: 9p24.2
Cellular Component: nucleoplasm; Golgi apparatus; nucleus
Molecular Function: metal ion binding
Biological Process: transcription from RNA polymerase II promoter; positive regulation of transcription from RNA polymerase II promoter; negative regulation of transcription from RNA polymerase II promoter
Disease: Diabetes Mellitus, Neonatal, With Congenital Hypothyroidism
Research Articles on GLIS3
1. analysis of a GLIS3 variant that may have a role in resistance to Japanese type 1 diabetes
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
